Sleep & Breathing Health Platforms technology and investment research

Technical bottleneck

Why it's a moat — DME reimbursement, connected device ecosystem, and compliance data

Sleep apnea treatment has three durable moats — and one emerging threat:

1. DME reimbursement lock-in: CPAP devices are classified as Durable Medical Equipment (DME) under Medicare Part B. Reimbursement requires: a sleep study diagnosis, a physician prescription, a 90-day compliance period (usage >4 hours/night on >70% of nights), and ongoing resupply (masks every 3 months, tubing every 6 months, filters every month). This creates a structured recurring revenue stream: once a patient is on CPAP and compliant, the resupply cycle is automatic and insurer-mandated. Switching to a competitor's device mid-cycle requires a new prescription and compliance period — friction that favors the incumbent.

2. Connected device ecosystem: AirSense 11 uploads nightly usage data to the cloud via cellular connection. myAir (patient app) provides daily sleep scores, coaching tips, and mask fit feedback. AirView (clinician portal) allows providers to monitor thousands of patients, adjust pressure settings remotely, and generate compliance reports for insurers. This connected ecosystem creates stickiness: a patient who switches to a non-connected CPAP loses the app integration, the automated resupply reminders, and the remote adjustment capability.

3. Compliance as a reimbursement requirement: Medicare and most commercial insurers require objective compliance data (device-reported usage hours) to continue reimbursement beyond the initial 90-day rental period. ResMed's connected platform provides this data automatically — a feature that DME suppliers and physicians rely on for revenue cycle management. This makes the compliance reporting infrastructure a soft but embedded switching cost.

The GLP-1 threat: Tirzepatide (SURMOUNT-OSA trial) showed ~50% reduction in apnea-hypopnea index (AHI) — meaning some OSA patients on GLP-1s may no longer meet the clinical threshold for CPAP therapy. If 20–30% of CPAP-eligible patients achieve sufficient weight loss to discontinue therapy, the device market faces a demand headwind. The counterargument: the OSA market is so underdiagnosed (80%+ undiagnosed) that even with GLP-1 attrition, diagnosis rates will outpace treatment discontinuation. But the risk is real and the market prices it.

Adoption

Why it matters now

ResMed (RMD):

• AirSense 11: auto-adjusting CPAP — the core product, connected via cellular
• AirCurve: bilevel for complex OSA, COPD overlap, central sleep apnea
• AirFit masks: nasal, full-face, pillow — recurring consumable revenue
• myAir app + AirView clinician portal: connected digital health platform
• Ventilation: Stellar, Astral, Lumis for chronic respiratory disease and hospital use
• Risk: June 2026 myAir data sync outage — widespread platform disruption
• Competition: GLP-1 drugs (tirzepatide) as alternative/adjunct therapy

Key trends

• GLP-1s as competitor, not complement: SURMOUNT-OSA showed 50% AHI reduction — this is a real therapeutic alternative for obesity-related OSA, not just a weight-loss side effect
• Underdiagnosis as the offset: 936M global OSA patients, ~80% undiagnosed. Even with GLP-1 attrition, the diagnosis funnel is so large that net patient growth can remain positive for years
• Digital health differentiation: Connected devices with cloud monitoring, app-based coaching, and automated resupply are the competitive differentiator — ResMed's ecosystem is the benchmark

Key players

Related Technologies

• Continuous Glucose Monitoring (CGM) — same "wearable + AI + recurring consumable" model; both face GLP-1 demand risk
• GLP-1 Demand Engine — the primary risk and potential complement to CPAP therapy
• Remote Cardiac Monitoring — both are remote monitoring businesses; similar payer and compliance dynamics